Chronic Myelogenous Leukemia - Treatment Options, Symptoms, Causes & Diagnosis from MedifocusHealth

Chronic Myelogenous Leukemia > What Your Doctor is Reading About Chronic Myelogenous Leukemia > Review Articles

Review Articles

1. Dual tyrosine kinase inhibitors in chronic myeloid leukemia.

Author: Martinelli G; Soverini S; Rosti G; Baccarani M;
Institution: Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy. gmartino@kaiser.alma.unibo.it
Journal: Leukemia. 2005 Nov;19(11):1872-9.
Abstract URL: Click here to view abstract

2. Autologous stem cell transplantation in chronic myeloid leukaemia: a meta-analysis of six randomized trials.

Author
Institution: CTSU, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF, UK. cmloverview@ctsu.ox.ac.uk
Journal: Cancer Treat Rev. 2007 Feb;33(1):39-47. Epub 2006 Dec 11.
Abstract URL: Click here to view abstract

3. Treatment of chronic myeloid leukemia with imatinib mesylate.

Author: Ohno R;
Institution: Aichi Cancer Center and Aichi Syukutoku University, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681, Japan. ohnoryu@aichi-cc.jp
Journal: Int J Clin Oncol. 2006 Jun;11(3):176-83.
Abstract URL: Click here to view abstract

4. Chronic myeloid leukemia: diagnosis and treatment.

Author: Quintas-Cardama A; Cortes JE;
Institution: Department of Leukemia, The University of Texas, M. D. Anderson Cancer Center, Houston, Tex 77030, USA.
Journal: Mayo Clin Proc. 2006 Jul;81(7):973-88.
Abstract URL: Click here to view abstract

5. New strategies in chronic myeloid leukemia.

Author: Kantarjian HM; Cortes J;
Institution: Department of Leukemia, The University of Texas, M. D. Anderson Cancer Center, Houston, Texas 77030, USA. hkantarj@mdanderson.org
Journal: Int J Hematol. 2006 May;83(4):289-93.
Abstract URL: Click here to view abstract

6. New targeted approaches in chronic myeloid leukemia.

Author: Cortes J; Kantarjian H;
Institution: Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA. jcortes@mdanderson.org
Journal: J Clin Oncol. 2005 Sep 10;23(26):6316-24.
Abstract URL: Click here to view abstract

7. Stem cell transplantation in patients with chronic myelogenous leukemia: when should it be used?

Author: Mauro MJ; Maziarz RT;
Institution: Center for Hematologic Malignancies, Oregon Cancer Institute, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, UHN73C, Portland, OR 97239, USA. maurom@ohsu.edu
Journal: Mayo Clin Proc. 2006 Mar;81(3):404-16.
Abstract URL: Click here to view abstract

8. Targeted CML therapy: controlling drug resistance, seeking cure.

Author: O'Hare T; Corbin AS; Druker BJ;
Institution: Howard Hughes Medical Institute, Oregon Health & Science University Cancer Institute, L592, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA.
Journal: Curr Opin Genet Dev. 2006 Feb;16(1):92-9. Epub 2005 Dec 15.
Abstract URL: Click here to view abstract

9. Targeted therapy in chronic myeloid leukemia.

Author: Jabbour E; Cortes JE; Ghanem H; O'Brien S; Kantarjian HM;
Institution: The University of Texas MD Anderson Cancer Center, Department of Leukemia, Unit 428, 1515 Holcombe Blvd, Houston, TX 77030, USA. ejabbour@mdanderson.org
Journal: Expert Rev Anticancer Ther. 2008 Jan;8(1):99-110.
Abstract URL: Click here to view abstract

10. Strategies for overcoming imatinib resistance in chronic myeloid leukemia.

Author: Kujawski L; Talpaz M;
Institution: Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109-0843, USA. kuj@med.umich.edu
Journal: Leuk Lymphoma. 2007 Dec;48(12):2310-22.
Abstract URL: Click here to view abstract

11. Targeted chronic myeloid leukemia therapy: Seeking a cure.

Author: Fausel C;
Institution: Hematology/Oncology/BMT, Indiana University Cancer Center, 550 North University Boulevard, Indianapolis, IN 46202, USA. cfausel@clarian.org
Journal: Am J Health Syst Pharm. 2007 Dec 15;64(24 Suppl 15):S9-15.
Abstract URL: Click here to view abstract

12. Chronic myeloid leukemia in 2007.

Author: Sessions J;
Institution: Hematology/Oncology, Emory University Hospital, 1364 Clifton Road, NE, Atlanta, GA 30322, USA. jolynn_sessions@emoryhealthcare.org
Journal: Am J Health Syst Pharm. 2007 Dec 15;64(24 Suppl 15):S4-9.
Abstract URL: Click here to view abstract

13. New strategies in controlling drug resistance in chronic myeloid leukemia.

Author: Frame D;
Institution: Department of Pharmacy, University of Michigan, 1500 Medical Center Drive, Ann Arbor, MI 48109, USA. dframe@med.umich.edu
Journal: Am J Health Syst Pharm. 2007 Dec 15;64(24 Suppl 15):S16-21.
Abstract URL: Click here to view abstract

14. Part II: management of resistance to imatinib in chronic myeloid leukaemia.

Author: Apperley JF;
Institution: Department of Haematology, Imperial College, Hammersmith Hospital, London, UK. j.apperley@imperial.ac.uk
Journal: Lancet Oncol. 2007 Dec;8(12):1116-28.
Abstract URL: Click here to view abstract

15. State-of-the-art in the treatment of chronic myeloid leukaemia.

Author: Milojkovic D; Apperley J;
Institution: Department of Haematology, The Hammersmith Hospital, London, UK. d.milojkovic@imperial.ac.uk
Journal: Curr Opin Oncol. 2008 Jan;20(1):112-21.
Abstract URL: Click here to view abstract

16. Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment.

Author: Jabbour E; Cortes J; Giles F; Kantarjian H;
Institution: Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Journal: Cancer J. 2007 Nov-Dec;13(6):357-65.
Abstract URL: Click here to view abstract

17. Management of Bcr-Abl-positive leukemias with dasatinib.

Author: Hochhaus A;
Institution: III. Medizinische Klinik, Abteilung Leukaemieforschung, Medizinische Fakultaet Mannheim, University of Heidelberg, 68167 Mannheim, Germany. hochhaus@uni-hd.de
Journal: Expert Rev Anticancer Ther. 2007 Nov;7(11):1529-36.
Abstract URL: Click here to view abstract

18. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.

Author: Steinberg M;
Institution: Department of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences, 19 Foster Street, Worcester, MA 01608, USA. michael.steinberg@mcphs.edu
Journal: Clin Ther. 2007 Nov;29(11):2289-308.
Abstract URL: Click here to view abstract

19. Treatment for chronic myelogenous leukemia: the long road to imatinib.

Author: Hunter T;
Institution: Molecular and Cell Biology Laboratory, Salk Institute for Biological Studies, La Jolla, California 92037-1099, USA. hunter@salk.edu
Journal: J Clin Invest. 2007 Aug;117(8):2036-43.
Abstract URL: Click here to view abstract

20. Chronic myeloid leukaemia.

Author: Hehlmann R; Hochhaus A; Baccarani M;
Institution: III Medizinische Universitatsklinik, Medizinische Fakultat Mannheim der Universitat Heidelberg, Mannheim, Germany. Ruediger.Hehlmann@med3.ma.uni-heidelberg.de
Journal: Lancet. 2007 Jul 28;370(9584):342-50.
Abstract URL: Click here to view abstract

21. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia.

Author: Schiffer CA;
Institution: Division of Hematology/Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 48201, USA. schiffer@karmanos.org
Journal: N Engl J Med. 2007 Jul 19;357(3):258-65.

22. Chronic myeloid leukemia--some topical issues.

Author: Mughal T; Cortes J; Cross NC; Donato N; Hantschel O; Jabbour E; Kantarjian H; Melo JV; Skorski T; Silver RT; Goldman JM;
Institution
Journal: Leukemia. 2007 Jul;21(7):1347-52. Epub 2007 May 10.

23. Resistance to targeted therapy in chronic myelogenous leukemia.

Author: Hochhaus A; Erben P; Ernst T; Mueller MC;
Institution: III. Medizinische Klinik, Medizinische Fakultat Mannheim, University of Heidelberg, Mannheim, Germany. hochhaus@uni-hd.de
Journal: Semin Hematol. 2007 Jan;44(1 Suppl 1):S15-24.
Abstract URL: Click here to view abstract

24. Imatinib: a review of its use in chronic myeloid leukaemia.

Author: Moen MD; McKeage K; Plosker GL; Siddiqui MA;
Institution: Wolters Kluwer Health, Adis, Auckland, New Zealand.
Journal: Drugs. 2007;67(2):299-320.
Abstract URL: Click here to view abstract

25. Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase.

Author: Atallah E; Cortes J;
Institution: Department of Leukemia, The University of Texas, M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
Journal: Curr Opin Hematol. 2007 Mar;14(2):138-44.
Abstract URL: Click here to view abstract

26. Pregnancies in patients with chronic myeloid leukemia in the era of imatinib.

Author: Koh LP; Kanagalingam D;
Institution
Journal: Int J Hematol. 2006 Dec;84(5):459-62.

27. New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance.

Author: Jabbour E; Cortes J; O'Brien S; Giles F; Kantarjian H;
Institution: Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Journal: Semin Hematol. 2007 Jan;44(1 Suppl 1):S25-31.
Abstract URL: Click here to view abstract

28. Optimal management of patients with newly diagnosed chronic phase chronic myeloid leukemia in 2007.

Author: Mughal T; Goldman JM;
Institution: Division of Hematology and Stem Cell Transplantation, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. tariq.mughal@utsouthwestern.edu
Journal: Clin Lymphoma Myeloma. 2007 Mar;7 Suppl 3:S95-101.
Abstract URL: Click here to view abstract

29. Allogeneic hematopoietic progenitor cell transplantation for the treatment of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors: lessons learned to date.

Author: Giralt S;
Institution: Department of Stem Cell Transplantation and Cellular Therapies University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. e-mail: sgiralt@notes.mdacc.tmc.edu
Journal: Clin Lymphoma Myeloma. 2007 Mar;7 Suppl 3:S102-4.
Abstract URL: Click here to view abstract

30. Emerging strategies for the treatment of mutant Bcr-Abl T315I myeloid leukemia.

Author: Mughal TI; Goldman JM;
Institution: Division of Hematology and Stem Cell Transplantation, University of Texas Southwestern Medical School, Dallas 75390, USA. tariq.mughal@utsouthwestern.edu
Journal: Clin Lymphoma Myeloma. 2007 Mar;7 Suppl 2:S81-4.
Abstract URL: Click here to view abstract

31. Immunotherapy in chronic myelogenous leukemia.

Author: Guilhot F; Roy L; Martineua G; Guilhot J; Millot F;
Institution: Department of Oncology-Hematology and Cell Therapy, Clinical Research Centre, Centre Hospitalier Universitaire de Poitiers, France. e-mail: f.guilhot@chu-poitiers.fr
Journal: Clin Lymphoma Myeloma. 2007 Mar;7 Suppl 2:S64-70.
Abstract URL: Click here to view abstract

32. Monitoring patients with chronic myeloid leukemia receiving Abl tyrosine kinase inhibitor therapy.

Author: Oehler V; Radich JP;
Institution: Clinical Research Division, Program in Genetics and Genomics, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Journal: Clin Lymphoma Myeloma. 2007 Mar;7 Suppl 2:S58-63.
Abstract URL: Click here to view abstract

33. Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges.

Author: Jabbour E; Cortes J; O'Brien S; Rios MB; Giles F; Kantarjian H;
Institution: Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Journal: Clin Lymphoma Myeloma. 2007 Mar;7 Suppl 2:S51-7.
Abstract URL: Click here to view abstract

34. Imatinib mesylate for the treatment of chronic myeloid leukemia.

Author: Soverini S; Martinelli G; Iacobucci I; Baccarani M;
Institution: Department of Hematology & Oncological Sciences "Lorenzo e Ariosto Seragnoli" University of Bologna, Via Massarenti 9, 40138 Bologna, Italy. simona.soverini@tin.it
Journal: Expert Rev Anticancer Ther. 2008 Jun;8(6):853-64.
Abstract URL: Click here to view abstract

35. Molecular diagnosis and monitoring in the clinical management of patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors.

Author: Ou J; Vergilio JA; Bagg A;
Institution: Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104-4283, USA.
Journal: Am J Hematol. 2008 Apr;83(4):296-302.
Abstract URL: Click here to view abstract

36. Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors?

Author: Maziarz RT;
Institution: Bone Marrow Transplantation Program, Oregon Health and Science University, Portland, Oregon 97201, USA. maziarzr@ohsu.edu
Journal: Curr Opin Hematol. 2008 Mar;15(2):127-33.
Abstract URL: Click here to view abstract

37. Homoharringtonine for the treatment of chronic myelogenous leukemia.

Author: Quintas-Cardama A; Cortes J;
Institution: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Unit 428, 1515 Holcombe Blvd., Houston, TX 77030, USA. aquintas@mdanderson.org
Journal: Expert Opin Pharmacother. 2008 Apr;9(6):1029-37.
Abstract URL: Click here to view abstract

38. Getting to the stem of chronic myeloid leukaemia.

Author: Savona M; Talpaz M;
Institution: University of Michigan, Internal Medicine-Hematology Oncology, 1500 East Medical Center Drive, Ann Arbor, Michigan 48109-45936, USA. msavona@med.umich.edu
Journal: Nat Rev Cancer. 2008 May;8(5):341-50.
Abstract URL: Click here to view abstract

39. Emerging drugs in chronic myelogenous leukaemia.

Author: Bocchia M; Forconi F; Lauria F;
Institution: Universita di Siena, Sezione di Ematologia e Trapianti, Dipartimento di Medicina Clinica e Scienze Immunologiche, AOUS, Viale Bracci--53100 Siena, Italy. bocchia@unisi.it
Journal: Expert Opin Emerg Drugs. 2006 Nov;11(4):651-64.
Abstract URL: Click here to view abstract

40. Management of patients with resistant or refractory chronic myelogenous leukemia.

Author: Quintas-Cardama A; Cortes J;
Institution: Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Journal: Oncology (Williston Park). 2008 Apr 15;22(4):430-7; discussion 437, 442, 446 passim.
Abstract URL: Click here to view abstract

41. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

Author: Baccarani M; Saglio G; Goldman J; Hochhaus A; Simonsson B; Appelbaum F; Apperley J; Cervantes F; Cortes J; Deininger M; Gratwohl A; Guilhot F; Horowitz M; Hughes T; Kantarjian H; Larson R; Niederwieser D; Silver R; Hehlmann R;
Institution: Department of Hematology-Oncology L. and A. Seragnoli, S. Orsola-Malpighi Hospital, Via Massarenti 9, 40138 Bologna, Italy. baccarani@med.unibo.it
Journal: Blood. 2006 Sep 15;108(6):1809-20. Epub 2006 May 18.
Abstract URL: Click here to view abstract

42. Hearing loss in chronic myeloid leukemia.

Author: Naithani, Rahul; Chandra, Jagdish; Mathur, N N; Narayan, Shashi; Singh, Varinder;
Institution: Division of Hematology, Department of Pediatrics, Kalawati Saran Children's Hospital, New Delhi 110001, India. dr_rahul6@hotmail.com
Journal: Pediatr Blood Cancer 2005 Jul;45(1):54-6.
Abstract URL: Click here to view abstract

43. Targeted cancer therapies.

Author: Blay, Jean-Yves; Le Cesne, Axel; Alberti, Laurent; Ray-Coquart, Isabelle;
Institution: Inserm Unit 590, Centre Leon Berard, 28 rue Laennec, 69008 Lyon, France. blay@fnclcc.lyon.fr
Journal: Bull Cancer 2005 Feb;92(2):E13-8.
Abstract URL: Click here to view abstract

44. Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia.

Author: Copland, M; Fraser, A R; Harrison, S J; Holyoake, T L;
Institution: ATMU, Section of Experimental Haematology, University Faculty of Medicine, Glasgow Royal Infirmary, 10 Alexandra Parade, Glasgow, G31 2ER, UK.
Journal: Cancer Immunol Immunother 2005 Apr;54(4):297-306. Epub 2004 Nov 30.
Abstract URL: Click here to view abstract

45. The development of imatinib as a therapeutic agent for chronic myeloid leukemia.

Author: Deininger, Michael; Buchdunger, Elisabeth; Druker, Brian J;
Institution: Oregon Health & Science University Cancer Institute, 3181 SW Sam Jackson Park Rd, Mailcode L592, Portland, OR 97239, USA. deininge@ohsu.edu
Journal: Blood 2005 Apr 1;105(7):2640-53. Epub 2004 Dec 23.
Abstract URL: Click here to view abstract